辛伐他汀治疗心脑血管疾病的临床疗效分析

Clinical Efficacy of Simvastatin in the Treatment of Cardiovascular and Cerebrovascular Diseases

目的分析辛伐他汀在心脑血管疾病患者中的临床治疗效果。方法选取所在医院2016年8月—2018年8月期间收治的90例心脑血管疾病患者,根据治疗方法分组,即对照组(口服阿司匹林,n=45)和观察组(阿司匹林+辛伐他汀,n=45),对比两组患者临床效果。结果观察组总有效率(95.56%)高于对照组(77.78%),差异有统计学意义(χ^2=5.012,P=0.019);观察组患者治疗后血浆APN水平、hs-CRP明显优于对照组(t=9.821、8.242,P=0.000、0.000);观察组治疗后神经功能(NIHSS)评分、Barthel指数均优于对照组患者治疗后(t=12.589、14.238,P=0.000、0.000);两组患者用药期间不良反应发生率(4.44%vs 11.11%)比较,差异无统计学意义(χ^2=0.142,P=0.237)。结论辛伐他汀辅助常规治疗,可有效改善患者预后,临床效果明显。

Objective To analyze the clinical therapeutic effect of simvastatin in patients with cardiovascular and cerebrovascular diseases.Methods A total of 90 patients with cardiovascular and cerebrovascular diseases admitted to the hospital from August 2016 to August 2018 were selected according to the treatment methods,namely the control group(oral aspirin,n=45)and the observation group(aspirin+simvastatin,n=45),compare the clinical effects of the two groups of patients.Results The total effective rate of the observation group(95.56%)was higher than that of the control group(77.78%).There was statistically significant difference between the two groups(χ^2=5.012,P=0.019).The plasma APN level and hs-CRP were significantly observed in the observation group.Compared with the control group(t=9.821,8.242,P=0.000,0.000);the neurological function(NIHSS)score and Barthel index of the observation group were better than those of the control group(t=12.859,14.238,P=0.000,0.000).The incidence of adverse reactions during the treatment of the two groups(4.44%vs 11.11%)was statistically significant not statistically significant(χ^2=0.142,P=0.237).Conclusion Simvastatin can improve the prognosis of patients with conventional treatment,and the clinical effect is obvious.